The recent health care changes and approval of a generic low-molecular-weight heparin (LMWH) by the US Food and Drug Administration (FDA) merit a review of the facts regarding the new and generic anticoagulants. Fatal hypotension from anaphylactoid type reactions following heparin administration was responsible for more than 149 deaths all over the world. Researchers detected a heparin-like semisynthetic contaminant, over-sulfated chondroitin sulfate (OSCS), that appeared to be intentional. Low-molecular-weight heparins are produced using unfractionated heparin and OSCS has been found in various batches of LMWHs. Some newer anticoagulants are claiming to be free from the need to monitor for therapeutic effect and bleeding risk. Therefore, monitoring assays are not being developed and there is no antidote to reverse bleeding. In addition, there are concerns about reproducibility, product variation, and quality. In conclusion, although the generic LMWHs and newer anticoagulants may appear to be effective for qualified indications, their safety remains to be a concern.
On July the 23rd, US Food and Drug Administration (FDA) approved the first generic low-molecular-weight heparin (LMWH). 1 This followed the recent health care overhaul that changed the way millions of Americans access their health care and health insurance requiring nearly everyone to have health insurance or face penalties. The time has come for affordable medication for everyone, but who is to guarantee the safety of these drugs? Patents for biologic agents first marketed in the 1980s are now beginning to expire, opening the door for ''non-proprietary'' versions of these agents to enter the market. However, there are differences between generics and biosimilars to the original innovator product in dimensions (molecular weight), synthesis, purification, stability, and immunogenicity. 2, 3 In early 2008, the US FDA recalled several batches of heparins due to the increased prevalence of adverse reactions and death. 4 Fatal hypotension from anaphylactoid type reactions was responsible for over 149 deaths all over the world. 5 Researchers detected a heparin-like semisynthetic contaminant namely over-sulfated chondroitin sulfate (OSCS) in significant amounts (5%-30%) that appeared to be intentional. 4, 6, 7 Varying degrees of high-molecular weight dermatan sulfate and heparan sulfate were also detected. 5, 8 Low-molecular-weight heparins are produced using unfractionated heparin (UFH), and OSCS has been found in various batches of LMWHs. 4, 8 A consensus conference on complex biologics and LMWHs was convened in Chicago in February 2010. It was held under the auspices of the North American Thrombosis Forum (NATF), the International Union of Angiology (IUA), and the South Asian Society of Atherosclerosis and Thrombosis (SASAT). The proceedings were published in International Angiology 9 and a summary was posted on the Web site of the above societies. [10] [11] [12] In addition, a special session was held at the XXIV IUA meeting in Buenos Aires in April 2010, to present and ratify the consensus statement of IUA. 13 On April 7, 2010, FDA issued a drug safety communication update alerting the public about changes to the heparin sodium USP monograph. 14 It points out that there is approximate 10% decrease in the anticoagulant activity (potency) of the ''new heparin'' compared with the ''old heparin.'' Health care professionals should exercise their clinical judgment in determining the dose of heparin.
Low MWHs are different pharmacologic entities. 15 Properties associated with one cannot be assumed to be the same as those associated with another. Consequently, therapeutic interchange of these agents is inappropriate. [15] [16] [17] The pharmacokinetic (PK) and pharmacodynamic (PD) differences among LMWH can be explained by comparing methods of preparation, molecular structures, half-lives, antithrombinmediated actions, non-antithrombin-mediated actions, effect on thrombus, and dosing interval. Low-molecular-weight heparin should be prescribed only for those indications for which they have been shown to be effective and only at dosages that have been studied. 15 A major clinical developmental consideration for new and generic anticoagulants and biosimilars is the adverse effect of bleeding. All anticoagulants will cause bleeding as an expected extension of their pharmacologic activity on the clotting cascade and hemostasis. Newer anticoagulants are marketed as being free from needing monitoring in most clinical conditions. Thus, monitoring assays have not been developed in parallel with the drug development. However, when bleeding does occur, it will be important to have an antidote available or a reversal methodology, as well as a reliable test to assure patient safety and appropriate clinical management. No antidote or reliable reversal methodology with clinical testing is currently available.
Orally bioavailable anticoagulant drugs (anti-Xa and anti-IIa agents), which are intended to replace oral anticoagulants, have provided impressive clinical outcomes in sponsor trials for the postoperative prophylaxis of VTE. 18 However, safety concerns related to liver enzyme elevations and thrombosis rebound have been reported with their use. For these reasons, the US FDA did not approve the orally active antithrombin agent ximelagatran for several indications. 19 The synthetic pentasaccharide (fondaparinux) has undergone an aggressive clinical development and also produced major bleeding problems at minimal dosages. 18 Different LMWH have been shown to have various effects on coagulation parameters. The mechanism behind the antithrombotic action of LMWH is not fully understood but is likely to involve inhibition of coagulation factors Xa and IIa, release of tissue-factor-pathway inhibitor, and inhibition of thrombinactivatable fibrinolytic inhibitor. 17 Laboratory monitoring of the anticoagulation effect of LMWHs is generally not necessary but should be considered in patients with morbid obesity (weight > 190 kg), those with severe renal impairment, and those with moderate renal impairment with prolonged (>10 days) LMWH use. Anti-Xa activity should be monitored by a chromogenic method and a calibration curve based on the LMWH used. [20] [21] [22] It is important that biosimilars or follow on biologics (FOB) are sufficiently tested to ensure patient safety is not compromised. Conducting such a development program followed by sound pharmacovigilance will be very challenging and costly. Therefore, cost-savings associated with these agents may be limited. 23 It is widely believed that acceptable bioequivalence studies of drugs with high within-participant pharmacokinetic (PK) variability must enroll higher numbers of participants than studies of drugs with lower variability. Observations from bioequivalence data submitted to the FDA for new generic drug applications were studied. They reviewed 1010 acceptable bioequivalence studies of 180 different drugs, of which 31% (57 of 180) were highly variable. They concluded that about 60% of the highly variable drugs were highly variable due to drug substance PK characteristics. For about 20% of the highly variable drugs, it appeared that formulation performance contributed to the high variability. 24 The heterogeneity of different LMWHs depends on different manufacturing processes and on particular specifications of pharmacopoeias. 25 While generic LMWHs may exhibit acceptable molecular weight and anti-FXa profiles, they can exhibit assay-based differences and digestion profiles. Testing in animal models to determine safety, efficacy, and PD parameters may be important to verify equivalence. In order to assure that the generic LMWHs are equivalent to branded LMWHs, there is a need to develop clear stepwise guidelines that will establish equivalency in terms of physical, chemical, biochemical, PK, and PD properties for these anticoagulants with adequate clinical trials. 26 The nonhemorrhagic adverse effects of the LMWHs include immunogenic conditions, such as heparin-induced thrombocytopenia (HIT), and osteoporosis. The incidence of HIT appears to be lower with LMWHs than with UFH; there are currently not enough data to compare the frequency of HIT between the various LMWHs. Low MWHs also appear to carry a lower risk of causing osteoporosis than UFH. 27 Biosimilars differ from generic chemical drugs in many important ways, including the size and complexity of the active substance, the nature of the starting materials (cell banks, tissues, and other biological products), and the complexity of the manufacturing processes. 28 Comparative testing with respect to protein content, activity, physiochemical integrity, stability, impurities, and additives, as well as immunogenicity and pharmacovigilance of biosimilars, is important. [29] [30] [31] Differences in the immunogenic responses among different branded LMWHs have been noted. These differences are due to the structural composition of the LMWH and the interactions with endogenous PF4 and related proteins. 32 Therefore, the clinical safety of similar biological medicinal products must be monitored closely on an ongoing basis during the postapproval phase including continued risk-benefit assessment. 33 The European Medicinal Agency (EMEA) in 2009 requested further clinical trials regarding the approval of generic LMWHs. 34, 35 In China, they undertook such a study. It was designed to determine the bioequivalence of generic and branded formulations of enoxaparin 60 mg in healthy participants for the purpose of meeting regulatory requirements for marketing the generic formulation in China. 36 The newer anticoagulants include the orally bioavailable anti-Xa and anti-IIa drugs. Most of these agents are synthetic LMWH drugs with varying degrees of bioavailability. Several of these drugs are currently in clinical development in various indications. Anti-Xa agent namely rivaroxaban (Xaletro) and a thrombin inhibitor namely dabigatran (Praxada) were approved in Canada and Europe for the prophylaxis of postsurgery deep venous thrombosis (DVT) in orthopedic patients. Although another factor Xa inhibitor namely apixaban is currently in advanced development, both rivaroxaban and dabigatran are at present under review by the FDA. The hepatotoxicity of all 3 is unknown. 37 There are several additional anti-Xa agents currently developed and are in various phases of clinical trials. The PK and PD actions of these drugs differ, and each agent exhibits a distinct safety and efficacy profile; bleeding complications have been reported with the use of all these agents. Moreover, myocardial infarction and dyspepsia were also reported with their use.
There is a need for monitoring of liver transaminases and bilirubin levels with the new oral anticoagulants for at least 2 years after marketing authorization. 37 The FDA guidance recommends that premarketing clinical evaluation is performed using available clinical databases to detect the potential of a drug to cause significant hepatotoxicity, particularly by altered liver function, demonstrated by an elevated alanine transaminase (ALT) > 3 of the upper limit of the normal range (ULN) plus elevated serum bilirubin. 38 Since all of these agents are synthetic organic molecules, their chemical effects are strongly influenced by metabolic variations among individuals. Accordingly, there is no antidote available for the normalization of the bleeding of these agents. While these drugs are promising anticoagulants for the compromised patients, these drugs are mostly monotherapeutic and do not exhibit a broad treatment spectrum at this time.
In summary, the concerns regarding the development of oral FXa and thrombin inhibitors are that: 1. They cross the blood brain and placental barriers. 2. They do not release tissue factor pathway inhibitor (TFPI). 3. They do not modulate the thrombin activatable fibrinolysis inhibitor. 4. After discontinuation of dosing, there is the potential of thrombin rebound. 5. Special population studies are needed beyond the idealized patients enrolled in the trials. 6. There is a need for specific management in renalcompromised patients. 7. The medical community should be alerted for adverse effects like bleeding, liver enzyme elevation, accumulation, contraindication in pregnancy, myocardial infarction. 8. Detection of any food, dietary supplement, and drug interactions. 9. Interference in laboratory assays. 10. There is no monitoring. 11. There is no antidote. 12. There is variation in response.
In conclusion, the generics undoubtedly decrease medicare reimbursements for the use of medication that are currently branded and expensive. Generic medications however have the criteria to match the PK and PD within a 80% to 125% range of the branded drug. 39 It has been proven repeatedly that biologically derived medications are not easily interchangeable even within the same class due to their indications, side effect, and safety profiles that have been studied in individual clinical trials designed specifically for them. The transition from branded to generic in the case of biologically derived drugs may therefore not be as simple keeping in mind the potential for immunogenicity and other issues mentioned in our paper without establishing safety profiles in clinical trials. The newer anticoagulants will definitely make an impact considering the level of monitoring is lesser with these medications in comparison to warfarin. It should also be emphasized that the newer oral anticoagulants are monotherapeautic and differ from one another in their mechanism of action and pharmacodynamic properties. Therefore, these medication need to be closely monitored even after FDA approval in order to completely understand the drug risk profile.
